© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Werewolf Therapeutics, Inc. (HOWL) stock declined over -3.26%, trading at $0.64 on NASDAQ, down from the previous close of $0.66. The stock opened at $0.65, fluctuating between $0.63 and $0.69 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Feb 25, 2026 | 0.64 | 0.69 | 0.63 | 0.64 | 838.1K |
| Feb 24, 2026 | 0.64 | 0.67 | 0.63 | 0.66 | 676.91K |
| Feb 23, 2026 | 0.66 | 0.68 | 0.63 | 0.66 | 553.75K |
| Feb 20, 2026 | 0.73 | 0.74 | 0.65 | 0.67 | 390.56K |
| Feb 19, 2026 | 0.67 | 0.73 | 0.66 | 0.72 | 483.36K |
| Feb 18, 2026 | 0.67 | 0.67 | 0.65 | 0.66 | 145.12K |
| Feb 17, 2026 | 0.66 | 0.67 | 0.62 | 0.66 | 237.54K |
| Feb 13, 2026 | 0.66 | 0.68 | 0.63 | 0.65 | 196.44K |
| Feb 12, 2026 | 0.68 | 0.69 | 0.64 | 0.66 | 222.94K |
| Feb 11, 2026 | 0.74 | 0.74 | 0.65 | 0.67 | 307.42K |
| Feb 10, 2026 | 0.68 | 0.73 | 0.68 | 0.72 | 552.86K |
| Feb 09, 2026 | 0.63 | 0.69 | 0.61 | 0.67 | 603.61K |
| Feb 06, 2026 | 0.65 | 0.65 | 0.60 | 0.61 | 204.33K |
| Feb 05, 2026 | 0.63 | 0.64 | 0.60 | 0.61 | 175.51K |
| Feb 04, 2026 | 0.66 | 0.66 | 0.59 | 0.64 | 312.26K |
| Feb 03, 2026 | 0.70 | 0.73 | 0.63 | 0.66 | 268.65K |
| Feb 02, 2026 | 0.67 | 0.69 | 0.62 | 0.68 | 452.29K |
| Jan 30, 2026 | 0.73 | 0.75 | 0.66 | 0.66 | 477.72K |
| Jan 29, 2026 | 0.74 | 0.75 | 0.68 | 0.72 | 340.8K |
| Jan 28, 2026 | 0.68 | 0.80 | 0.68 | 0.71 | 1.03M |
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
| Employees | 46 |
| Beta | 0.78 |
| Sales or Revenue | $19.94M |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |